<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Immucell Corporation — News on 6ix</title>
<link>https://6ix.com/company/immucell-corporation</link>
<description>Latest news and press releases for Immucell Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 20:38:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/immucell-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835816978dffbe2df0fbd68.webp</url>
<title>Immucell Corporation</title>
<link>https://6ix.com/company/immucell-corporation</link>
</image>
<item>
<title>ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillemette-and-dr-anthony-dimarco-to-the-board-and-moves-to-a-smaller-board-of-independent-directors</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillemette-and-dr-anthony-dimarco-to-the-board-and-moves-to-a-smaller-board-of-independent-directors</guid>
<pubDate>Mon, 13 Apr 2026 20:38:00 GMT</pubDate>
<description>PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will c</description>
</item>
<item>
<title>ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-a-284percent-increase-in-product-sales-in-q1-of-2026-based-on-preliminary-unaudited-sales-results</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-a-284percent-increase-in-product-sales-in-q1-of-2026-based-on-preliminary-unaudited-sales-results</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that</description>
</item>
<item>
<title>ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-appoints-former-elanco-animal-health-board-member-kathy-turner-to-board</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-appoints-former-elanco-animal-health-board-member-kathy-turner-to-board</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that</description>
</item>
<item>
<title>ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-for-the-year-ended-december-31-2025-136</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-for-the-year-ended-december-31-2025-136</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops,</description>
</item>
<item>
<title>ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-to-announce-unaudited-financial-results-for-the-quarter-and-year-ended-december-31-2025</guid>
<pubDate>Wed, 18 Feb 2026 13:37:00 GMT</pubDate>
<description>Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ETPORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a conference cal</description>
</item>
<item>
<title>ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-210500405</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-210500405</guid>
<pubDate>Thu, 08 Jan 2026 21:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Compan</description>
</item>
<item>
<title>ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-conduct-conference-call-investors-131000525</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-conduct-conference-call-investors-131000525</guid>
<pubDate>Wed, 07 Jan 2026 13:10:00 GMT</pubDate>
<description>Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ETPORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and</description>
</item>
<item>
<title>ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-strategic-focus-first-180500895</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-strategic-focus-first-180500895</guid>
<pubDate>Wed, 24 Dec 2025 18:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expand</description>
</item>
<item>
<title>ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-210500197</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-210500197</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $</description>
</item>
<item>
<title>ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announce-unaudited-financial-results-210500690</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announce-unaudited-financial-results-210500690</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Conference Call Scheduled for Friday, November 14, 2025 at 9:00 AM ETPORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, Novem</description>
</item>
<item>
<title>ImmuCell Announces Onboarding of New CEO and Related Management Changes</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-onboarding-ceo-related-210500689</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-onboarding-ceo-related-210500689</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Bri</description>
</item>
<item>
<title>ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-200500677</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-200500677</guid>
<pubDate>Tue, 07 Oct 2025 20:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line resul</description>
</item>
<item>
<title>ImmuCell Announces Selection of its Next President and CEO</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-selection-next-president-200500355</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-selection-next-president-200500355</guid>
<pubDate>Mon, 29 Sep 2025 20:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently</description>
</item>
<item>
<title>ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-200500180</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-200500180</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2025. Product Sales Highlights: During the second quarter of 2025, product sales increased by 18% to approximately $6.4</description>
</item>
<item>
<title>ImmuCell Announces Bank Debt Refinancing</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-bank-debt-refinancing-200500095</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-bank-debt-refinancing-200500095</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has successfully refinanced a portion of its bank debt. Management’s Discussion: Proceeds from a new loan from Maine Community Bank (MCB) in the principal amount of $2,327,119, be</description>
</item>
<item>
<title>ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announce-unaudited-financial-results-120000692</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announce-unaudited-financial-results-120000692</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ETPORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2025 after the market closes on Thursday, August 14, 2</description>
</item>
<item>
<title>ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-120000483</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-preliminary-unaudited-sales-120000483</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line resu</description>
</item>
<item>
<title>ImmuCell Embarks on CEO Succession Planning Process</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-embarks-ceo-succession-planning-120000376</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-embarks-ceo-succession-planning-120000376</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO. “I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time</description>
</item>
<item>
<title>ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-hold-virtual-only-annual-103000962</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-hold-virtual-only-annual-103000962</guid>
<pubDate>Thu, 05 Jun 2025 10:30:00 GMT</pubDate>
<description>PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statem</description>
</item>
<item>
<title>ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025</title>
<link>https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-200500900</link>
<guid isPermaLink="true">https://6ix.com/company/immucell-corporation/news/immucell-announces-unaudited-financial-results-200500900</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 m</description>
</item>
</channel>
</rss>